Cost-effectiveness analysis of cervical cancer screening strategies based on the papanicolaou smear test in Korea
- Authors
- Ko, M.J.; Kim, J.; Kim, Y.; Lee, Y.J.; Hong, S.R.; Lee, J.K.
- Issue Date
- 2015
- Publisher
- Asian Pacific Organization for Cancer Prevention
- Keywords
- Cancer screening; Cervical cancer; Economic evaluation; HPV infection; Pap smear test
- Citation
- Asian Pacific Journal of Cancer Prevention, v.16, no.6, pp.2317 - 2322
- Indexed
- SCIE
SCOPUS
- Journal Title
- Asian Pacific Journal of Cancer Prevention
- Volume
- 16
- Number
- 6
- Start Page
- 2317
- End Page
- 2322
- URI
- https://scholar.korea.ac.kr/handle/2021.sw.korea/95882
- DOI
- 10.7314/APJCP.2015.16.6.2317
- ISSN
- 1513-7368
- Abstract
- Background: Despite the increasing number of screening examinations performed for cervical cancer utilizing the Papanicolaou smear test (Pap test), few studies have examined whether this strategy is cost-effective in Korea. Objective: This study was conducted to evaluate the cost-effectiveness of cervical cancer screening strategies incorporating the Pap test based on age at the start and end of screening as well as screening interval. Materials and Methods: We designed four alternative screening strategies based on patient age when screening was started (20 or 30 years) and discontinued (lifetime, 79 years). Each strategy was assessed at screening intervals of 1, 2, 3, or 5 years. A Markov model was developed to determine the cost-effectiveness of the 16 possible cervical cancer screening strategies, and this was evaluated from a societal perspective. The main outcome measures were average lifetime cost, incremental quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratio (ICER). Results: Compared with various strategies comprising younger starting age, discontinuation age, and longer screening intervals, strategies employing annual screening for cervical cancer starting at a target age of 30 years and above were the most cost-effective, with an ICER of 21,012.98 dollars per QALY gained (with a Korean threshold of 30,000,000 KRW or US$27,272). Conclusions: We found that annual screening for cervical cancer beginning at a target age of 30 years and above is most cost-effective screening strategy. Considering the potential economic advantages, more intense screening policies for cervical cancer might be favorable among countries with high rates of cervical cancer and relatively low screening costs.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - College of Medicine > Department of Medical Science > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.